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IntRoductIon
Thyroid hormones (THs) are necessary for metabolic 
function of  the kidneys. The kidney is an organ for 
metabolism and elimination of  THs and a target of  some 
of  the iodothyronines’ actions. Thyroid dysfunction may 
effect on glomerular and tubular functions and electrolyte 
and water (H2O) homeostasis. It may cause a reduction in 
glomerular filtration, hyponatremia, and H2O excretion 
alteration.[1‑3] Many studies have shown that patients on 
regular hemodialysis (HD) tolerate a chronic illness which 
was not involved the thyroid, but these patients indicated low 
serum thyroxin (T4) and triiodothyronine (T3) levels.[4,5] Some 
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studies revealed decreased T3 and T4 levels while the 
thyroid‑stimulating hormone (TSH) levels are not elevated.[6] 
There may be an association between THs and the oxidative 
and antioxidative status in the body. It has been reported that 
thyroid dysfunction such as hypothyroidism reduces oxidant 
production which may not protect the organism against 
oxidant damage.[7,8] There are limited and controversial studies 
on the oxidative status of  hypothyroidism.[9‑11] Different 
antioxidant enzymes may protect oxidative effects of  free 
radicals on lipids, proteins, and DNA. These enzymes consist 
of  superoxide dismutase (SOD) and catalase (CAT).[12] SOD 
catalyzes the alteration of  the superoxide anion into hydrogen 
peroxide (H2O2). H2O2 then changed to H2O by CAT or 
glutathione peroxidase.[13,14] Lipid peroxidation which express 
as malondialdehyde (MDA) may change in different age and 
ethnic groups, gender and different kinds of  diseases.[15‑21] 
HD is the most effective method in balancing the metabolic 
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abnormalities related to renal oxidative stress that causes to 
morbidity in HD patients.[22] Chronic renal failure (CRF) 
patients who are on HD therapy show a high percentage 
of  goiter and thyroid dysfunction and cardiovascular (CV) 
disorders.[23‑25] Free radicals have been revealed to change 
the activity of  some membrane‑bound tissue enzymes.
[26] End‑stage renal disease can only be overcome by 
hemodialysis which can be considered as crucial therapeutic 
regiments for such kidney diseases and for those subjects 
which are a candidate for kidney transplantation.[27] The 
production of  reactive oxygen species (ROS) which are the 
byproducts of  hemodialysis therapy is the main obstacle and 
complications in hemodialysis application for the end stage 
renal failure.[28‑30] THs can be altered due to hemodialysis. The 
THs abnormality may accompany with various disorders, 
including systemic acidosis, the hemodialysis duration, and 
endothelial injuries and inflammation.[31] The aim of  this 
study focused on serum MDA levels which is an indicator of  
lipid peroxidation and erythrocyte SOD and CAT activities 
in hemodialysis patients and compared with age‑matched 
control groups in Gorgan.
mateRIals and metHods
Forty‑five hemodialyzed patients with mean age 
51.88 ± 15.90 years who were referred to the HD unit 
at 5th Azar Education Hospital of  Gorgan Faculty of  
Medicine, Golestan University of  Medical Sciences in 
Gorgan, Iran in 2015. Patients were compared with 45 
age‑matched control groups (mean age 48.68 ± 15.60). 
This study was approved by the Research Deputy Ethics 
Committee of  the Golestan University of  Medical Sciences. 
An informed consent from all subjects had been carried 
out. HD patients were being treated 3 times a week. Clinical 
history test was performed from all patients. Patients with 
diabetes mellitus, liver disease, endocrinal diseases, acute or 
chronic illness, thyroid disorders and any drug that affect 
TH were excluded from the study. A 10 ml blood samples 
were provided after an overnight fast of  12 h. Biochemical 
tests including serum creatinine and urea, THs (TSH, T3, 
T4, free triiodothyronine [fT3] and free thyroxin [fT4]) and 
erythrocyte antioxidant enzymes (SOD [Code number: 
706002, Cayman Chemical Commercial Kit, Colorimetric 
Method, USA] and CAT [Code Number: 707002, Cayman 
Chemical Commercial Kit, Colorimetric Method, USA]) 
were determined. The hormonal analysis was done by 
Monobind Kit (Code Number: 1225‑300, Lake Forest 
CA: 92630, USA) and enzyme immunoassay (ELISA) 
method. Serum creatinine and urea levels were determined 
with commercial kits by spectrophotometer techniques 
(Model JENWAY 6105 UV/VIS) in the Metabolic Disorders 
Research Center (Gorgan Faculty of  Medicine). Serum 
MDA was determined with Kei Satoh method.[32] Weight 
was measured, while subjects were minimally clothed 
without shoes, using digital scales. Height was measured in 
standing position using tape meter while the shoulder was 
in a normal position. Body mass index (BMI) was defined 
as weight in kilograms divided by height in meters squared. 
Overweight was defined as BMI 25.0–29.9 kg/m2 and obese 
as BMI ≥30 kg/m2.[33]
The results are shown as means and standard deviations. 
SPSS version 16 (SPSS Inc., Chicago, IL, USA) software 
was used to calculate the statistical analysis. The evaluation 
of  data was done by using independent sample t‑test 
and Pearson correlation test. P < 0.05 was considered 
statistically significant.
Results
Table 1 shows clinical and anthropometric characteristics 
of  the HD patients and control groups. There was no 
difference in serum TSH, age, and BMI among the studied 
groups. There were well‑significant differences in serum 
T3, T4, fT3 and fT4, MDA, SOD, and CAT compared 
with control groups. HD patients showed higher levels 
of  MDA than those control groups (P < 0.01), but the 
levels of  T3, fT3 and fT4, SOD and CAT were low in HD 
patients (P <0.01). Table 2 shows relationship between 
MDA SOD and CAT and THs in HD patients. Spearman 
correlation analysis showed that the serum T3, fT3, and 
fT4 levels were significantly negative correlated with 
MDA [Table 2]. There was no correlation between THs 
and SOD and CAT.
dIscussIon
In the present study, we revealed that the thyroid function 
differed among the HD group compared to the healthy 
Table 1: Clinical data of study subjects
Parameters Healthy 
subjects
Hemodialysis 
patients
P
n 45 45 ‑
Age (years) 48.68±15.6 51.88±15.9 0.330
BMI (kg/m2) 26.41±2.81 25.92±6.67 0.653
TSH (mIU/mL) 2.13±0.84 2.76±2.21 0.079
T3 (ng/mL) 1.25±0.25 0.83±0.32 0.001
T4 (μg/dL) 7.97±1.17 7.53±2.12 0.222
fT3 (pg/mL) 2.78±0.43 2.51±0.59 0.013
fT4 (ng/dL) 1.35±0.18 0.92±0.31 0.001
Creatinine (mg/dL) 0.91±0.77 10.03±1.92 0.001
Urea (mg/dL) 24.72±2.65 103.86±25.9 0.001
SOD (U/mL) 0.15±0.04 0.08±0.13 0.002
CAT (nmol/min/mL) 16.43±7.04 12.31±6.80 0.001
MDA (nmol/mL) 0.45±1.14 2.98±0.89 0.001
BMI: Body mass index, TSH: Thyroid‑stimulating hormone, fT3: Free 
triiodothyronine, fT4: Free thyroxin, SOD: Superoxide dismutase, CAT: Catalase, 
MDA: Malondialdehyde, T3: Triiodothyronine, T4: Thyroxin
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controls. Serum T3, fT3, and fT4 levels were lower; TSH 
was slightly higher, and T4 was unchanged among those 
with HD. Serum lipid peroxidation and antioxidant enzyme 
activities were significantly high and low among the HD 
group compared to the healthy controls, respectively. Some 
studies have shown a low serum level of  T3 in patients with 
end‑stage renal disease (ESRD).[34‑41] Lim et al.[35] reported 
a reduced T3 level and decreased conversion of  T4 to T3 
in uremic patients.[35] It is also revealed low serum T4 or 
fT4 levels in patients undergoing maintenance HD.[5,36,37,39,40] 
The serum TSH level in patients with CRF[34‑37,41,42] had 
been reported to be almost normal. Our study showed that 
the serum TSH level in the HD patients slightly increased 
and serum fT3 and fT4 level significantly decreased which 
is in agreement with other studies.[5,39,40,43‑51] In our study, 
slightly increase of  TSH level in hemodialyzed patients in 
comparison to control groups was not in accordance with 
others studies.[52] The increase in the serum TSH level 
was not obvious in HD patients. The low serum fT4 and 
fT3 levels may be responsible for the low metabolism of  
the body. Studies on a uremic rat model have shown that 
there may be a difference in the TH metabolism or action in 
the peripheral system and in the central nervous system in 
the ESRD patients.[53,54]  Xess et al. showed that CRF patients 
revealed a significant decrease in T3 (in accordance with our 
study) and T4 (not in accordance with our study) levels in 
comparison to control groups,[6,41,55] but serum TSH levels 
indicated no significant difference in patients and control 
groups which was in agreement with other findings.[55] The 
movement of  TH into and out of  the extravascular space 
may be a possible mechanism of  TH changes related to 
HD.[6] There are different findings on variations in serum 
lipid peroxidation level and erythrocyte antioxidant enzyme 
activities due to HD. Some studies indicated an increase 
while some show a decrease in the levels. In our study, we 
determined the level of  serum MDA of  HD patients. MDA 
uses as a specific and sensitive biomarker for the estimation 
of  the lipid peroxidation status in different diseases,[56] 
including in patients under chronic HD treatment.[57] 
Our results show a significant increase of  serum MDA 
in the HD group when compared with the control group. 
Oxidative damage may depend on different risk factors, but 
it can be caused by the imbalance between the productions 
of  free radicals and different anti‑oxidant enzymes.[58] 
Lipid peroxidation disrupts the structural integrity of  the 
lipid bilayer, leading to elevated membrane permeability 
(the release of  hydrolytic enzymes and increasing cell 
damage) and subsequent impaired electron transport for 
oxidative phosphorylation in mitochondria and increased 
lysosomal permeability.[59] The results of  present study 
indicate that significant difference of  anti‑oxidant enzyme 
activities between HD and control group may be related 
with the loss of  antioxidant enzymes, and the reduction 
of  antioxidant enzymes may be related to elevation of  
lipid peroxidation in hemodialyzed patients which is in 
agreement with findings of  other studies.[58,60,61] These 
results show that oxidants and anti‑oxidants imbalance may 
play an important role in the pathogenesis of  some diseases. 
Some findings showed that the elevated MDA level may act 
as a metabolic signal for kidney damage and protein leakage 
including THs.[62] It is reported that there is a significant 
increase of  the blood SOD and CAT activity in plasma 
and red blood cells of  patients undergoing hemodialysis.[61] 
Some other studies also indicated that the activity of  
erythrocyte SOD and CAT increased significantly[63,64] while 
another finding showed a decrease of  antioxidant enzymes 
in erythrocyte of  CRF patients.[65‑69] Study on hemodialyzed 
patients showed that significantly lower plasma CAT 
activity was found.[65] Study on the animal model kidney 
of  the cytoplasmic SOD has revealed the decrease of  the 
SOD protein abundance in the kidney tissues of  the CRF 
animals which is in accordance with findings that reported 
the decrease of  SOD enzymatic activity in the erythrocytes 
of  patients with CRF[70‑72] and in our results. We found 
significantly positive correlation between T3, fT3, and fT4 
and MDA, which is not in agreement with other studies.[42] 
This correlation between MDA and above mentioned TH 
levels indicate that the alteration of  these hormone levels 
in hemodialyzed patients may depend on variations of  lipid 
peroxidation in these patients. Reduced serum fT3 and T3 
may also relate to impaired extrathyroidal changing of  T4 
to T3. The alteration of  T4 and fT4 are less considered in 
these patients.[73] The exact mechanisms for the decrease 
of  T3 are not well known, but some studies have shown 
that the decreased T3 level correlates with poor cardiac 
prognosis and a strong predictor of  death in cardiac 
patients.[74] Decreased fT3 is not only important in CRF 
patients but also in acute and chronic infections; diabetes; 
and different CV diseases.[74] Studies have shown that T3 
and fT3 are as survival markers in patients with CKD and in 
Table 2: Correlation analyses between oxidative stress 
biomarkers and thyroid hormones in hemodialysis 
subjects
Parameters CAT SOD MDA
TSH r=−0.016
P=0.883
r=−0.071
P=0.506
r=0.037
P=0.730
T3 r=0.153
P=0.150
r=0.186
P=0.08
r=−0.499*
P=0.001
fT3 r=−0.145
P=0.173
r=0.057
P=0.593
r=−0.321*
P=0.002
T4 r=−0.039
P=0.716
r=−0.167
P=0.125
r=−0.161
P=0.129
fT4 r=0.172
P=0.104
r=0.239
P=0.053
r=−0.521*
P=0.001
*r= ‑0.499, P=0.001, SOD: Superoxide dismutase, CAT: Catalase, 
MDA: Malondialdehyde, TSH: Thyroid‑stimulating hormone, T3: Triiodothyronine, 
T4: Thyroxin, fT3: Free triiodothyronine, fT4: Free thyroxin
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HD patients.[75] Some researchers have suggested that there 
is a relationship between T3 levels and thyroid dysfunction 
and risk of  mortality in these patients.[76]
conclusIon
Thyroid dysfunction in HD patients is more common than 
in general population. HD may influences thyroid function 
in various ways. Serum lipid peroxidation is markedly 
increased in HD patients. This means that elevated ROS 
may interact with the lipid molecules in HD patients. Our 
results suggest that HD may cause significant changes in 
TH levels. TSH level in HD patients is slightly similar to 
that of  control groups. This suggests that thyroid is able 
to re‑synthesize for hormonal urinary losses. Because of  
the high prevalence of  thyroid dysfunction in HD patients, 
it suggests that screening of  thyroid function should be 
needed.
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